Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation HSCT

Trial Profile

A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation HSCT

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2018

At a glance

  • Drugs Anti CD19 chimeric antigen receptor T cell therapy Cellular Biomedicine Group (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2018 Planned End Date changed from 15 Dec 2019 to 30 Apr 2021.
    • 21 Sep 2018 Planned primary completion date changed from 15 Oct 2019 to 28 Feb 2021.
    • 21 Sep 2018 Planned initiation date changed from 15 May 2018 to 15 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top